Adipokines as Predictors of Foot Function, Pain, and Disability in Patients With Rheumatoid Arthritis

Rheumatoid Arthritis Clinical Trial

Official title: Foot Bone Mineral Density and Inflammation in Rheumatoid Arthritis

Status Completed

Clinical Trial Summary

Significant increase in the levels of serum adiponectin, ADA, and hsCRP was reported in all RA patients compared to controls.

Compared to patients with early RA, the increase in these markers significantly correlated with disease activity (DAS-ESR), lower f-BMD, radiographic scoring, pain, FFI, and functional limitations in patients with established RA.

Adiponectin showed a negative correlation with serum levels of both ADA and hsCRP. By using ROC curve analysis, optimal cut-off values of adiponectin (28.8 µg/ml), ADA (27.3 IU/L), and hsCRP (1.6 mg/L) could be used to estimate early RA in 45 % of the patients. Similarly, using cut-off values of adiponectin (32.8 µg/ml), ADA (26.1 IU/L ml), and hsCRP (2.5 mg/L), established RA could be predicted in 55 % of patients with 98-99% accuracy.

Clinical Trial Description

The present study attempts to evaluate the efficacy of adiponectin, ADA, and foot bone mineral density (fBMD) as predictors of the disease progression in patients with rheumatoid arthritis. A total of 80 RA patients and eighty age and sex-matched healthy controls were included in this study. ;

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Rheumatoid
• Healthy Control
• Rheumatoid Arthritis

• NCT number: NCT04036669
• Study type: Observational
• Source: King Saud University
• Status: Completed
• Start date: February 20, 2014
• Completion date: May 30, 2015